Dana-Farber Cancer Institute: Multiple Myeloma trials

The registry lists 30 Multiple Myeloma studies with Dana-Farber Cancer Institute as lead sponsor. 4 are open to participants now and 12 have results posted.

Early Phase 1 1Phase 1 7Phase 2 15Phase 3 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingNCT07624513Phase 3
• Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingNCT07601100Phase 1/2
• Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationRecruitingNCT05706766Not applicable
• Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Enrolling by invitationNCT03689595
• PROFAST Intervention in Precursor Multiple MyelomaCompletedNCT05565638Not applicableResults posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
• Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple MyelomaTerminatedNCT01484314Phase 2Results posted
• Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00903968Phase 1/2Results posted
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT00378209Phase 2Results posted
• Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00378105Phase 1/2Results posted
• Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaCompletedNCT00153920Phase 2Results posted
• CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingNCT05767359Phase 2
• Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2
• An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
• Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaNo longer availableNCT02666209
• GO-203-2C + Bortezomib For Relapsed Or Refractory MMWithdrawnNCT02658396Phase 1
• A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
• Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple MyelomaCompletedNCT01955395Not applicable
• Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in VitroCompletedNCT01472627
• SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)CompletedNCT01402687
• Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCTCompletedNCT01286675Early Phase 1
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
• CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell TransplantationCompletedNCT00333190Not applicable
• Protein Tyrosine Kinases (PTK) in Multiple MyelomaCompletedNCT00165347Phase 2
• Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1